📰 Tom Graney News
Page 3 - Tom Graney News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tom Graney. Real-time updates on events, politics, business and more.
June 23, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 23, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets ...
June 23, 2023
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage
June 15, 2023
Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical... | June 15, 2023
June 15, 2023
Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 3 of funding under the Subscription Agreement with Atlas Special Opportunities LLC ("Atlas”). On June 15, 2023, the Company issued 40 convertible bonds to Atlas totaling EUR one...
June 12, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 12, 2023 – 8.00 PM CET Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic... | June 12, 2023
June 6, 2023
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special
June 1, 2023
Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 8.00 AM CET – Oxurion NV , a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with... | June 1, 2023
June 1, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 7.00 PM CET Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic... | June 1, 2023
June 1, 2023
Regulated Information Leuven, BELGIUM, Boston, MA, US - June 1, 2023 - 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic
May 31, 2023
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 22 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Atlas